Tags

Type your tag names separated by a space and hit enter

Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: a preliminary report.
Antivir Ther. 2012; 17(6):1091-6.AT

Abstract

Hepatitis E virus (HEV) is a common cause of acute on chronic liver failure (ACLF) in HEV hyperendemic regions with high mortality. Treatment for HEV-induced ACLF is currently not available. Recently, efficacy of ribavirin in genotype 3 chronic hepatitis E patients has been reported; however, whether ribavirin is effective in genotype 1 HEV infection is not yet known. The present study includes four patients with HEV-induced ACLF treated with ribavirin in a genotype 1 HEV hyperendemic region. Diagnosis of ACLF was made by conventional criteria and HEV as the cause of ACLF was confirmed by detection of HEV RNA by reverse transcriptase PCR. Ribavirin dose ranged from 200 to 600 mg/day and was used for a median duration of 12 (range 3-24) weeks. All patients had undetectable HEV in 3-8 weeks, survived and none had serious adverse effects. This preliminary observation from a single centre indicates that ribavirin may be an effective therapeutic agent for HEV-induced ACLF and a randomized control trial is needed to establish its efficacy.

Authors+Show Affiliations

Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

22910532

Citation

Goyal, Rohit, et al. "Ribavirin Therapy for Hepatitis E Virus-induced Acute On Chronic Liver Failure: a Preliminary Report." Antiviral Therapy, vol. 17, no. 6, 2012, pp. 1091-6.
Goyal R, Kumar A, Panda SK, et al. Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: a preliminary report. Antivir Ther. 2012;17(6):1091-6.
Goyal, R., Kumar, A., Panda, S. K., Paul, S. B., & Acharya, S. K. (2012). Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: a preliminary report. Antiviral Therapy, 17(6), 1091-6. https://doi.org/10.3851/IMP2317
Goyal R, et al. Ribavirin Therapy for Hepatitis E Virus-induced Acute On Chronic Liver Failure: a Preliminary Report. Antivir Ther. 2012;17(6):1091-6. PubMed PMID: 22910532.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: a preliminary report. AU - Goyal,Rohit, AU - Kumar,Ajay, AU - Panda,Subrat K, AU - Paul,Shashi B, AU - Acharya,Subrat K, Y1 - 2012/08/16/ PY - 2011/11/29/accepted PY - 2012/8/23/entrez PY - 2012/8/23/pubmed PY - 2013/1/11/medline SP - 1091 EP - 6 JF - Antiviral therapy JO - Antivir Ther VL - 17 IS - 6 N2 - Hepatitis E virus (HEV) is a common cause of acute on chronic liver failure (ACLF) in HEV hyperendemic regions with high mortality. Treatment for HEV-induced ACLF is currently not available. Recently, efficacy of ribavirin in genotype 3 chronic hepatitis E patients has been reported; however, whether ribavirin is effective in genotype 1 HEV infection is not yet known. The present study includes four patients with HEV-induced ACLF treated with ribavirin in a genotype 1 HEV hyperendemic region. Diagnosis of ACLF was made by conventional criteria and HEV as the cause of ACLF was confirmed by detection of HEV RNA by reverse transcriptase PCR. Ribavirin dose ranged from 200 to 600 mg/day and was used for a median duration of 12 (range 3-24) weeks. All patients had undetectable HEV in 3-8 weeks, survived and none had serious adverse effects. This preliminary observation from a single centre indicates that ribavirin may be an effective therapeutic agent for HEV-induced ACLF and a randomized control trial is needed to establish its efficacy. SN - 2040-2058 UR - https://www.unboundmedicine.com/medline/citation/22910532/Ribavirin_therapy_for_hepatitis_E_virus_induced_acute_on_chronic_liver_failure:_a_preliminary_report_ L2 - http://www.diseaseinfosearch.org/result/3334 DB - PRIME DP - Unbound Medicine ER -